Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5707496 | 0.87 | SIGMAR1 (0.65) | CHRM2SIGMAR1HPGDALOX15DRD2 | |
| SCHEMBL6231722 | 0.86 | CHRM2 (0.85) | CHRM2KDM4ESCN8AALOX15SIRT2 | |
| SCHEMBL16741961 | 0.86 | CHRM2 (0.92) | CHRM2KDM4ESCN8AALOX15SIRT2 | |
| SCHEMBL29761156 | 0.84 | CHRM2 (0.66) | CHRM2KDM4ESCN8AALOX15TDP1 | |
| SCHEMBL9184672 | 0.84 | CHRM2 (0.89) | CHRM2KDM4ESCN8AALOX15SIRT2 | |
| SCHEMBL9777421 | 0.82 | CHRM2 (0.93) | CHRM2KDM4ESCN8AALOX15SIRT2 | |
| Hydrochloric Acid SCHEMBL10698987 | 0.82 | CHRM2 (0.86) | CHRM2KDM4ESCN8AALOX15SIRT2 | |
| SCHEMBL9188072 | 0.82 | CHRM2 (0.86) | CHRM2KDM4ESCN8AALOX15SIRT2 | |
| SCHEMBL9777408 | 0.82 | CHRM2 (0.86) | CHRM2KDM4ESCN8AALOX15SIRT2 | |
| SCHEMBL348655 | 0.82 | CHRM2 (0.78) | CHRM2KDM4ESCN8AALOX15SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1415986-B1 | SPIRO ISOBENZOFURANES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | BANYU PHARMA CO LTD (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-7205417-B2 | Spiro compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-20040259890-A1 | Spiro compounds | MSD K.K. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1415986-A1 | SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259890-A1 | Spiro compounds | OPRD1, PER2, OPRK1 | CHRM2 128/4885KDM4E 2787/4885SIGMAR1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.